These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33667455)

  • 1. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19.
    Pitt B; Sutton NR; Wang Z; Goonewardena SN; Holinstat M
    Eur J Pharmacol; 2021 May; 898():173988. PubMed ID: 33667455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral Coagulopathy in Patients With COVID-19: Treatment and Care.
    Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J
    Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity.
    Saiz ML; DeDiego ML; López-García D; Corte-Iglesias V; Baragaño Raneros A; Astola I; Asensi V; López-Larrea C; Suarez-Alvarez B
    Clin Epigenetics; 2021 Oct; 13(1):187. PubMed ID: 34635175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-β signalling in COVID-19 survivors.
    P KM; Sivashanmugam K; Kandasamy M; Subbiah R; Ravikumar V
    Life Sci; 2021 Feb; 266():118883. PubMed ID: 33316266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19.
    Mostafa-Hedeab G; Al-Kuraishy HM; Al-Gareeb AI; Jeandet P; Saad HM; Batiha GE
    Inflammopharmacology; 2022 Jun; 30(3):799-809. PubMed ID: 35486310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.
    Shawki MA; Elsayed NS; Mantawy EM; Said RS
    Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):395-409. PubMed ID: 34057871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.
    Bikdeli B; Madhavan MV; Gupta A; Jimenez D; Burton JR; Der Nigoghossian C; Chuich T; Nouri SN; Dreyfus I; Driggin E; Sethi S; Sehgal K; Chatterjee S; Ageno W; Madjid M; Guo Y; Tang LV; Hu Y; Bertoletti L; Giri J; Cushman M; Quéré I; Dimakakos EP; Gibson CM; Lippi G; Favaloro EJ; Fareed J; Tafur AJ; Francese DP; Batra J; Falanga A; Clerkin KJ; Uriel N; Kirtane A; McLintock C; Hunt BJ; Spyropoulos AC; Barnes GD; Eikelboom JW; Weinberg I; Schulman S; Carrier M; Piazza G; Beckman JA; Leon MB; Stone GW; Rosenkranz S; Goldhaber SZ; Parikh SA; Monreal M; Krumholz HM; Konstantinides SV; Weitz JI; Lip GYH;
    Thromb Haemost; 2020 Jul; 120(7):1004-1024. PubMed ID: 32473596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19.
    Saul S; Einav S
    ACS Infect Dis; 2020 Sep; 6(9):2304-2318. PubMed ID: 32687696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Ineluctable Role of ACE-2 Receptors in SARS COV-2 Infection and Drug Repurposing as a Plausible SARS COV-2 Therapy: A Concise Treatise.
    Joseph S; Nair B; Nath LR
    Curr Mol Med; 2021; 21(10):888-913. PubMed ID: 33563197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy for Prevention and Management of Thrombosis in COVID-19.
    Hashemi A; Madhavan MV; Bikdeli B
    Semin Thromb Hemost; 2020 Oct; 46(7):789-795. PubMed ID: 32820478
    [No Abstract]   [Full Text] [Related]  

  • 11. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opposing Effects of Valproic Acid Treatment Mediated by Histone Deacetylase Inhibitor Activity in Four Transgenic
    Vent-Schmidt RYJ; Wen RH; Zong Z; Chiu CN; Tam BM; May CG; Moritz OL
    J Neurosci; 2017 Jan; 37(4):1039-1054. PubMed ID: 28490005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
    Zhao L; Chen CN; Hajji N; Oliver E; Cotroneo E; Wharton J; Wang D; Li M; McKinsey TA; Stenmark KR; Wilkins MR
    Circulation; 2012 Jul; 126(4):455-67. PubMed ID: 22711276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia, HIF-1α, and COVID-19: from pathogenic factors to potential therapeutic targets.
    Serebrovska ZO; Chong EY; Serebrovska TV; Tumanovska LV; Xi L
    Acta Pharmacol Sin; 2020 Dec; 41(12):1539-1546. PubMed ID: 33110240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives for repurposing drugs for the coronavirus disease 2019.
    Cherian SS; Agrawal M; Basu A; Abraham P; Gangakhedkar RR; Bhargava B
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):160-171. PubMed ID: 32317408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC Inhibition as Potential Therapeutic Strategy to Restore the Deregulated Immune Response in Severe COVID-19.
    Ripamonti C; Spadotto V; Pozzi P; Stevenazzi A; Vergani B; Marchini M; Sandrone G; Bonetti E; Mazzarella L; Minucci S; Steinkühler C; Fossati G
    Front Immunol; 2022; 13():841716. PubMed ID: 35592335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
    Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK
    Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality.
    Al-Kuraishy HM; Al-Gareeb AI; Al-Hussaniy HA; Al-Harcan NAH; Alexiou A; Batiha GE
    Int Immunopharmacol; 2022 Mar; 104():108516. PubMed ID: 35032828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
    Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.